Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status.

被引：0
|
作者：
Kharenko, Olesya A. [1 ]
Patel, Reena [1 ]
Calosing, Cyrus [1 ]
机构：
[1] Zenith Epigenet, Calgary, AB, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1129
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
    Liang, Xuan-Bing
    Dai, Zhi-Cheng
    Zou, Rong
    Tang, Ji-Xin
    Yao, Cui-Wei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [32] EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER plus breast cancer cells
    Lypova, Nadiia
    Lanceta, Lilibeth
    Dougherty, Susan M.
    Chesney, Jason A.
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2022, 82 (12)
  • [33] Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
    Goel, Shom
    Wang, Qi
    Watt, April C.
    Tolaney, Sara M.
    Dillon, Deborah A.
    Li, Wei
    Ramm, Susanne
    Palmer, Adam C.
    Yuzugullu, Haluk
    Varadan, Vinay
    Tuck, David
    Harris, Lyndsay N.
    Wong, Kwok-Kin
    Liu, X. Shirley
    Sicinski, Piotr
    Winer, Eric P.
    Krop, Ian E.
    Zhao, Jean J.
    CANCER CELL, 2016, 29 (03) : 255 - 269
  • [34] CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
    Tanja K. Eggersmann
    Tom Degenhardt
    Oleg Gluz
    Rachel Wuerstlein
    Nadia Harbeck
    BioDrugs, 2019, 33 : 125 - 135
  • [35] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [36] CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
    Eggersmann, Tanja K.
    Degenhardt, Tom
    Gluz, Oleg
    Wuerstlein, Rachel
    Harbeck, Nadia
    BIODRUGS, 2019, 33 (02) : 125 - 135
  • [37] CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2+ Breast Cancer
    Malumbres, Marcos
    CANCER CELL, 2016, 29 (03) : 243 - 244
  • [38] Novel ERX-11 and CDK4/6 inhibitor combination therapy for treating therapy resistant breast cancer
    Viswanadhapalli, Suryavathi
    Sareddy, Gangadhara Reddy
    Ma, Shi-Hong
    Lee, Tae-Kyung
    Tekmal, Rajeshwar Rao
    Ahn, Jung-Mo
    Raj, Ganesh
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2017, 77
  • [39] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
    Formisano, Luigi
    Lu, Yao
    Servetto, Alberto
    Hanker, Ariella B.
    Jansen, Valerie M.
    Bauer, Joshua A.
    Sudhan, Dhivya R.
    Guerrero-Zotano, Angel L.
    Croessmann, Sarah
    Guo, Yan
    Ericsson, Paula Gonzalez
    Lee, Kyung-Min
    Nixon, Mellissa J.
    Schwarz, Luis J.
    Sanders, Melinda E.
    Dugger, Teresa C.
    Cruz, Marcelo Rocha
    Behdad, Amir
    Cristofanilli, Massimo
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Nagy, Rebecca J.
    Lanman, Richard B.
    Solovieff, Nadia
    He, Wei
    Miller, Michelle
    Su, Fei
    Shyr, Yu
    Mayer, Ingrid A.
    Balko, Justin M.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [40] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Luigi Formisano
    Yao Lu
    Alberto Servetto
    Ariella B. Hanker
    Valerie M. Jansen
    Joshua A. Bauer
    Dhivya R. Sudhan
    Angel L. Guerrero-Zotano
    Sarah Croessmann
    Yan Guo
    Paula Gonzalez Ericsson
    Kyung-min Lee
    Mellissa J. Nixon
    Luis J. Schwarz
    Melinda E. Sanders
    Teresa C. Dugger
    Marcelo Rocha Cruz
    Amir Behdad
    Massimo Cristofanilli
    Aditya Bardia
    Joyce O’Shaughnessy
    Rebecca J. Nagy
    Richard B. Lanman
    Nadia Solovieff
    Wei He
    Michelle Miller
    Fei Su
    Yu Shyr
    Ingrid A. Mayer
    Justin M. Balko
    Carlos L. Arteaga
    Nature Communications, 10
12345